Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation

Submitted: 6 March 2013
Accepted: 27 August 2013
Published: 24 December 2013
Abstract Views: 1221
PDF: 807
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The patients with non-valvular atrial fibrillation (NVAF), both permanent and paroxysmal, and history of previous transient ischemic attack (TIA) or stroke represent a category of patients at high risk of new embolic events, independently of the presence of other risk factors. In these patients, national and international guidelines recommend oral anticoagulants as first choice for antithrombotic prevention. Direct oral anticoagulants (DOACs) have been demonstrated to be not inferior to warfarin for many end points in NVAF patients in terms of efficacy and safety. The post hoc analysis in selected subgroups of patients enrolled in the three mega trials of phase III comparing DOACs (RE-LY, ROCKET-AF and ARISTOTLE) with warfarin help to evaluate whether superiority and non-inferiority persist in these subgroups. Here, patients with NVAF and history of previous TIA/stroke receiving DOACs as secondary prevention are compared with patients with the same characteristics receiving warfarin. An analysis of these patients has been recently published (separately for each of three DOACs). This analysis shows that DOACs maintain their non-inferiority when compared with warfarin in secondary prevention, representing a real alternative in this context of patients at high risk for ischemic and bleeding events.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Supporting Agencies

none

How to Cite

Masotti, L., Di Napoli, M., Ageno, W., Imberti, D., Becattini, C., Paciaroni, M., Godoy, D. A., Cappelli, R., Landini, G., Panigada, G., Iori, I., Prisco, D., & Agnelli, G. (2013). Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation. Italian Journal of Medicine, 7(s8), 8–21. https://doi.org/10.4081/itjm.2013.s8.8

Similar Articles

You may also start an advanced similarity search for this article.

List of Cited By :

Crossref logo